Literature DB >> 33551954

Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management.

James E Galvin1, Paul Aisen2, Jessica B Langbaum3, Eric Rodriguez4, Marwan Sabbagh5, Richard Stefanacci6, Robert A Stern7, Elizabeth A Vassey7, Arno de Wilde8, Neva West9, Ivana Rubino9.   

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disease that creates complex challenges and a significant burden for patients and caregivers. Although underlying pathological changes due to AD may be detected in research studies decades prior to symptom onset, many patients in the early stages of AD remain undiagnosed in clinical practice. Increasing evidence points to the importance of an early and accurate AD diagnosis to optimize outcomes for patients and their families, yet many barriers remain along the diagnostic journey. Through a series of international working group meetings, a diverse group of experts contributed their perspectives to create a blueprint for a patient-centered diagnostic journey for individuals in the early stages of AD and an evolving, transdisciplinary care team. Here, we discuss key learnings, implications, and recommendations.
Copyright © 2021 Galvin, Aisen, Langbaum, Rodriguez, Sabbagh, Stefanacci, Stern, Vassey, de Wilde, West and Rubino.

Entities:  

Keywords:  Alzheimer's disease; dementia; diagnosis; early detection; mild cognitive impairment

Year:  2021        PMID: 33551954      PMCID: PMC7863984          DOI: 10.3389/fneur.2020.592302

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  28 in total

1.  The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial.

Authors:  Barbara G Vickrey; Brian S Mittman; Karen I Connor; Marjorie L Pearson; Richard D Della Penna; Theodore G Ganiats; Robert W Demonte; Joshua Chodosh; Xinping Cui; Stefanie Vassar; Naihua Duan; Martin Lee
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

2.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

3.  Nonpharmacological Interventions to Improve Depression, Anxiety, and Quality of Life (QoL) in People With Dementia: An Overview of Systematic Reviews.

Authors:  Naoko Kishita; Tamara Backhouse; Eneida Mioshi
Journal:  J Geriatr Psychiatry Neurol       Date:  2019-06-16       Impact factor: 2.680

Review 4.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

5.  Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.

Authors:  Sandrine Andrieu; Sophie Guyonnet; Nicola Coley; Christelle Cantet; Marc Bonnefoy; Serge Bordes; Lawrence Bories; Marie-Noëlle Cufi; Thierry Dantoine; Jean-François Dartigues; Françoise Desclaux; Audrey Gabelle; Yannick Gasnier; Alain Pesce; Kristel Sudres; Jacques Touchon; Philippe Robert; Olivier Rouaud; Philippe Legrand; Pierre Payoux; Jean-Paul Caubere; Michael Weiner; Isabelle Carrié; Pierre-Jean Ousset; Bruno Vellas
Journal:  Lancet Neurol       Date:  2017-03-27       Impact factor: 44.182

6.  Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement.

Authors:  Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2020-02-25       Impact factor: 56.272

7.  Supply and demand analysis of the current and future US neurology workforce.

Authors:  Timothy M Dall; Michael V Storm; Ritashree Chakrabarti; Oksana Drogan; Christopher M Keran; Peter D Donofrio; Victor W Henderson; Henry J Kaminski; James C Stevens; Thomas R Vidic
Journal:  Neurology       Date:  2013-04-17       Impact factor: 9.910

8.  Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity.

Authors:  Lampros C Kourtis; Oliver B Regele; Justin M Wright; Graham B Jones
Journal:  NPJ Digit Med       Date:  2019-02-21

9.  Issues and Questions Surrounding Screening for Cognitive Impairment in Older Patients.

Authors:  Ronald C Petersen; Kristine Yaffe
Journal:  JAMA       Date:  2020-02-25       Impact factor: 157.335

10.  The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.

Authors:  Craig W Ritchie; Tom C Russ; Sube Banerjee; Bob Barber; Andrew Boaden; Nick C Fox; Clive Holmes; Jeremy D Isaacs; Ira Leroi; Simon Lovestone; Matt Norton; John O'Brien; Jim Pearson; Richard Perry; James Pickett; Adam D Waldman; Wai Lup Wong; Martin N Rossor; Alistair Burns
Journal:  Alzheimers Res Ther       Date:  2017-10-26       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.